Daix (France), September 10, 2021 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company's first-half financial results for 2021 on Tuesday, September 21, 2021.

Inventiva's 2021 first-half financial results will be released on Monday, September 20, 2021 at 4:00 pm (New York), 10:00 pm (Paris).

Frédéric Cren, Chairman, CEO and cofounder of Inventiva and Jean Volatier, Chief Financial Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Tuesday, September 21, 2021 at 8:00 am (New York), 2:00 pm (Paris).

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/2kk6k5k7. They will also be available on Inventiva's website in the "Investors" – "Financial results" section.

To join the conference call, please use the code 8573858 after dialing one of the following numbers:

France: +33 1 70 70 07 81

Belgium: +32 27 93 38 47

Germany: +49 69 22 22 26 25

Netherlands: +31 20 79 56 614

Switzerland: +41 44 58 07 145

United Kingdom: +44 207 19 28 338

United States: +1 646-741-3167

Please note that the line will be opened 10 minutes before the start of the conference call.

A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (NASDAQ:IVA) and on the Nasdaq Global Market in the United States (NASDAQ:IVA). www.inventivapharma.com

Contacts

Inventiva

Pascaline Clerc

VP of Global External Affairs

media@inventivapharma.com

+1 240 620 9175

Brunswick Group

Yannick Tetzlaff /

Tristan Roquet Montegon /

Aude Lepreux

Media relations

inventiva@brunswickgroup.com

+33 1 53 96 83 83

Westwicke, an ICR Company

Patricia L. Bank

Investor relations

Patti.bank@westwicke.com

+1 415 513 1284

Attachment

Inventiva - PR - EN - Webcast invitation H1 2021 - 09 10 2021

Inventiva's 2021 First-Half Financial Results Presentation